Leo Cancer Care secured $65 million in a Series D round to expand development and deployment of its upright proton platform across countries, the company said. The capital is earmarked for manufacturing, accelerating commercialization, and advancing clinical and product development for an integrated treatment platform. The financing highlights continued investor appetite for radiation modalities positioned as capacity multipliers—particularly as health systems evaluate throughput, patient access, and operational complexity of advanced oncology systems. With dedicated funding for both deployment and clinical/product work, Leo Cancer Care’s next milestones are likely to focus on scaling installation while maintaining clinical evidence generation in parallel.